ELOVL-6

ELOVL6 (elongation of very long-chain fatty acids protein 6) catalyzes the elongation of C12-C16 saturated and monounsaturated fatty acids, functioning as a microsomal rate-limiting enzyme in fatty acid biosynthesis^[1][2][3]. Mechanistically, ELOVL6 activity modulates lipid composition in hepatocytes, mammary epithelial cells, and chondrocytes, thereby influencing energy metabolism, insulin sensitivity, and cellular differentiation^[1][2][3]. Compared with other ELOVL isoforms, ELOVL6 shows distinct substrate specificity for medium-chain fatty acids, while ELOVL2, ELOVL5, and ELOVL4 preferentially elongate polyunsaturated fatty acids or very long-chain fatty acids^[4][3]. In disease models, overexpression of ELOVL6 contributes to nonalcoholic steatohepatitis (NASH) progression by promoting hepatosteatosis, oxidative stress, and inflammasome activation^[1]. Additionally, ELOVL6 positively correlates with breast cancer aggressiveness and poor prognosis, indicating its role in lipid-mediated oncogenic signaling^[5]. In hematopoietic and leukemia models, ELOVL6 regulates CXCL12-CXCR4-dependent chemotaxis through PI3K-Rac1 signaling, with pharmacologic inhibition impairing cell migration^[6]. For experimental applications, ELOVL6 modulation via overexpression or knockdown has been employed to investigate lipid synthesis, chondrocyte differentiation, and metabolic phenotypes in mammalian and aquatic systems^[2][3]. Tissue-specific expression studies reveal elevated ELOVL6 in liver, intestine, mammary gland, and hepatopancreas, highlighting its relevance for metabolic research and functional genomics^[7][3][8]. Collectively, ELOVL6 represents a key elongase with isoform-specific biological functions, disease associations, and versatile utility in experimental models^[1][2][3][8].